**Core tip:** It was considered that the endoscopic retrograde cholangiopancreatography for biliopancreatic diseases in patients with Billroth II-reconstructed stomach will become a less invasive, safe and useful examination and treatment approach.

INTRODUCTION
============

With the development of endoscopic techniques, equipment and treatment tools in recent years, the endoscopic approach for biliopancreatic diseases is rapidly evolving, and less invasive treatment has become possible. Moreover, it can be said that the necessity for endoscopic retrograde cholangiopancreatography (ERCP)-related procedures is increasing because of improvement of the results of surgical operation and postoperative careful follow-up in patients after gastrectomy. In patients after gastrectomy, however, the difficulty in procedures is high because the methods of approach to the papilla and anastomosis are different according to the anatomy by reconstruction method and because the physical relationship of the papilla is different endoscopically. In the present study, we performed ERCP on cases of biliopancreatic disease in patients with Billroth II-reconstructed stomach to examine its utility and safety.

MATERIALS AND METHODS
=====================

The subjects included 26 patients with Billroth II-reconstructed stomach, who have biliopancreatic diseases and have attempted the ERCP 42 times in total from April 1999 to February 2010. There were 21 male and 5 female patients, with the mean age of 70.2-year-old (ranging from 59-year-old to 89-year-old). The diseases were bile duct stone in 20 patients, intrahepatic stone in 1 patient, papilla vater cancer in 1 patient, gallbladder cancer in 1 patient, cholangiocarcinoma in 1 patient, pancreatic cancer in 1 patient and biliary obstruction due to peritoneal metastasis of gastric cancer in 1 patient. One patient underwent diagnostic ERCP, and 25 patients underwent therapeutic ERCP (Table [1](#T1){ref-type="table"}).

###### 

Patients' background and disease background

  **Sex**                                          **21 males** **5 females**
  --------------- -------------------------------- ----------------------------
  Age                                              70.2 yr (range: 59-89 yr)
  Disease         Bile duct stone                  20
                  Intrahepatic stone               1
                  Papilla vater cancer             1
                  Gallbladder cancer               1
                  Cholangiocarcinoma               1
                  Pancreatic cancer                1
                  Metastatic biliary obstruction   1
  Target region   Bile duct                        25
                  Pancreatic duct                  1
  Purpose         Diagnosis                        1
                  Treatment                        25

Among the 42 total procedures, a straight-view scope and a retrograde oblique-viewing endoscope were used 24 and 18 times, respectively (Q200, 230, 240, XQ200, PCF240, JF230 and JF240: Olympus Corp, Tokyo, Japan). For cannulation, catheters PR-104Q, R110Q-1 and PR233Q were used. A 0.025-inch or 0.035-inch guidewire (Jagwire by Microvasive, Boston Scientific Corp, Natick, MA, United States or Revo Wave by Olympus Corp) was used. For endoscopic papillary balloon dilatation (EPBD), the balloon was selected according to the diameter of the bile duct and dilated at 4 atmospheres until the notch disappeared (OLBERT by Maeadox Surgimed Corp, or QUANTUM by Boston Scientific Corp). Endoscopic sphincterotomy (EST) was conducted using a single electrosurgical current generator (PSD-20; Olympus Corp) at a power of 25 W. For incision, the needle-knife (KD10Q-1; Olympus Corp) was used.

When the endoscope reached the duodenal papilla or anastomosis, when insertion into the bile duct or pancreatic duct became possible and when the purposes, including treatment, were achieved, the cases were considered successful. The endoscopic nasobiliary drainage tube (ENBD) of 7 Fr was used (Flexima; Boston Scientific Corp, or SD9 by SILUX). The tube stents of 7 Fr and 8.5 Fr were used (FLEXIMA, SOLOPASS: Boston Scientific Corp). As a metal stent, Flexxus (Kobayashi Medical) uncovered-type was used. Basket catheters (FG-22Q; Olympus Corp) were used for stone quarry, and LBGT-7245S (ZEON Medical) was used for lithotripsy. The rate of reaching the duodenal papilla or anastomosis, the success rate of insertion into bile duct in patients with achievement and the success rate of treatment were examined.

The endoscope and procedures were selected at the discretion of the operating surgeon. All the patients had provided written informed consent before these diagnostic and therapeutic procedures. Iatrogenic morbidity was assessed according to the criteria of Cotton et al\[[@B1]\].

RESULTS
=======

The rate of reaching the duodenal papilla or anastomosis was 84.7% (22/26 patients). The Braun anastomosis was observed at a rate of 38.5% (10/26 patients). Among the cases not reaching the papilla or anastomosis, there were 2 in which the endoscope did not pass due to tumor-induced duodenal infiltration. In 1 case, the fiber did not reach the duodenal papilla due to long afferent loop. The success rate of insertion into bile duct in the patients in which the endoscope reached the papilla or anastomosis was 90.9% (20/22 patients). As treatment of papilla, the EPBD and EST were conducted on 18 and 2 patients, respectively. The remaining 1 patient was a patient with intrahepatic stone, who underwent choledochojejunostomy, and since no stenosis of anastomosis was observed, the treatment was started with no procedure for the anastomosis. In the patients with bile duct stone (Figure [1](#F1){ref-type="fig"}), the mean diameter of stone was 8.6 mm (range of 0 mm to 16 mm), and the number of stones ranged from 0 to 1.5, with 2 patients having spontaneous elimination of stones and showing no stone in cholangiography. All these patients succeeded in collection of stones.

![Endoscopic retrograde cholangiopancreatography on bile duct stone in athe patient with Billroth II-reconstructed stomach. A: Stones, sized 7 mm, were observed by cholangiography; B: Stones were gripped with a basket, and collection of stone was successful.](WJGE-9-127-g001){#F1}

Among the 42 ERCP procedures conducted, drainage was performed 15 times, and the ENBD, placement of tube stent and placement of metallic stent were attempted 9 times, 5 times and 1 time, respectively (Figure [2](#F2){ref-type="fig"}), all of which were successful. The success rate of treatment was 86.3% (19/22 patients). The one patient who succeeded in cholangiography but failed in treatment was the one with intrahepatic stone who underwent choledochojejunostomy and who failed in lithotripsy because the guidewire passed through stones to the side of liver but the catheter did not pass. On that patient, percutaneous transhepatic cholangioscopic lithotripsy was performed after percutaneous transhepatic biliary drainage (PTBD), and the treatment was successful. In the present treatment, mild cholangitis was observed in 1 patient (4.5%, 1/22 patient) but was relieved conservatively. No other accidental symptom was observed. Among 4 patients in which the endoscope did not reach the duodenal papilla, 3 patients underwent PTBD. One patient had bile duct stone with no hepatic disorder, and surgery was conducted instead of PTBD. Among 2 patients in which the endoscope reached the papilla but the biliary cannulation was impossible, 1 patient underwent the PTBD and another patient was the one with gallbladder cancer showing no jaundice, and on this patient, the ERCP was conducted for the purpose of diagnosis, which was not successful, so the image of bile duct was substituted with magnetic resonance cholangiopancreatography (MRCP).

![Endoscopic retrograde cholangiopancreatography on obstructive jaundice in the a patient with Billroth II-reconstructed stomach. A: Intense stenosis was observed from the upper through middle bile duct by cholangiography; B: The endoscopic nasobiliary drainage tube was placed after placement of a metallic stent.](WJGE-9-127-g002){#F2}

DISCUSSION
==========

The patients with biliopancreatic diseases after gastrectomy have experienced open surgery once. In the non-gastrectomized patients, repeated open surgery for the diseases such as bile duct stone, in which the endoscopic treatment becomes the first option, puts a heavy strain on the patients. In recent years, both the rate of reaching the duodenal papilla and the success rate of the procedure have been reported to be relatively good from various institutions for the patients with Billroth II-reconstructed stomach\[[@B2]-[@B20]\]. Since the afferent loop is relatively short in the patients with Billroth II-reconstructed stomach, different from the Roux-en-Y-reconstructed stomach, reaching the papilla may frequently be possible even using a straight-view scope or a retrograde oblique-viewing endoscope.

In our present results, the rate of reaching the duodenal papilla and anastomosis was 87.5%, the success rate of cholangiography was 90.5%, and the procedural success rate was 85.7%. Among the patients in which the endoscope did not reach the duodenal papilla and anastomosis, the fiber did not pass due to tumor-induced infiltration in 2 patients. It is shown that, if there is no problem in the passage of fiber and if the fiber can reach the area, the procedure has a high probability of being successful. In the remaining 1 patient of our study, the fiber did not reach the duodenal papilla due to long afferent loop. When the fiber is too short to reach the papilla with a straight-view scope or a retrograde oblique-viewing endoscope, there is a possibility that this problem can be resolved by using a single balloon enteroscopy\[[@B18]\] or a double balloon\[[@B19],[@B20]\] with a long effective length.

Concerning attainment to the duodenal papilla in the patients with the Billroth II-reconstructed stomach, moreover, it is said that the presence or absence of Braun anastomosis may have a large influence on the rate of reaching the papilla. The results in the patients with no Braun anastomosis are good, but those in the patients with Braun anastomosis are bad. Ciçek et al\[[@B11]\] reported that the rate of reaching the papilla was 29% in the patients with Braun anastomosis. In the patients with Braun anastomosis, when endoscopy is conducted indefinitely, it may induce repeated round trip of the same route and become a waste of time. It is integral to aim at attainment to the papilla having a clear strategy so as not to neglect to confirm the direction of movement at the anastomosis. Concerning the route into which the endoscope has ever entered, for example, it is considered necessary to mark with clips, *etc*.

As to the fiber, we used a straight-view scope or a retrograde oblique-viewing endoscope. With a straight-view scope, it is easy to secure the field of view of the lumen of the intestinal tract during insertion of the endoscope into the small intestine, which is superior to the retrograde oblique-viewing endoscope from the aspect of prevention of perforation. Since the usual straight view scope has a small inlet of forceps, however, the available devices have some limitations. With the retrograde oblique-viewing endoscope, on the other hand, it is difficult to obtain the field of view of the lumen of the gastrointestinal tract, and insertion of the endoscope into the small intestine is difficult. In the past, there have been a lot of reports of perforation of 0.7% to 18% with a retrograde oblique-viewing endoscope, compared with that of a straight-view endoscope\[[@B6]-[@B15]\]. In many cases, the blinded manipulation of endoscope may be associated with this. Since the retrograde oblique-viewing endoscope has a longer effective length than the straight-view endoscope and has a bending forceps device after reaching the papilla, however, it is effective for selective cannulation. In recent years, very good results have been obtained by an anterograde oblique-viewing endoscope having the same effective length and the same field of view as the straight-view scope and a bending forceps device\[[@B21],[@B22]\]. At present, there is a problem of effective length, but in the case of Billroth II-reconstructed stomach, this fiber can become the first option.

In the patients with Billroth II-reconstructed stomach, however, this method may be difficult because the oppositely-oriented approach should be conducted different from the usual ERCP. In the patients for whom the fiber reached the papilla in this study, the success rate of cannulation was as high as 90.9%. This report does not have inferiority in comparison with the results of an anterograde oblique-viewing endoscope\[[@B21],[@B22]\]. The reason why the success rate was high despite that this patient represented a case with difficulty in cannulation, in which the papilla existed on the opposite side from the usual one, was because the flexible tip catheter\[[@B23]\], *etc*., with which the angle can be changed in cannulation, was used. Since the success rate was not 100%, despite the high success rate, improved techniques of operators and further modification of treatment tools are required.

Concerning the treatment of papilla, the EST and EPBD have been performed. Different from the usual ERCP, it is difficult to perform EST with a needle knife because the oppositely-oriented approach should be performed. If we wish to perform EST because it is advantageous for subsequent treatment of giant bile duct stone, it should be used because there is a papillotome effective for the Billroth II-reconstructed stomach different from usual papillotome\[[@B5],[@B10]\], if EST with a needle knife is technically difficult. Different from the EST, on the other hand, if a guidewire is placed in the bile duct, it may be possible to perform treatment easily with EPBD, even if using usual treatment tools. Therefore, choledocholithiasis in the patients with Billroth II-reconstructed stomach is considered a good indication for EPBD unless otherwise specified.

In the present study, however, we have not experienced cases with pancreatitis as an accidental symptom; but, since EPBD is a risk factor of post-ERCP pancreatitis\[[@B24],[@B25]\], it is considered very important to perform prevention against pancreatitis due to placement of pancreatic stent\[[@B26],[@B27]\] in the patients undergoing erroneous pancreatography or patients in whom a guidewire was erroneously inserted into the pancreatic duct. Considering that stones were spontaneously eliminated in 2 patients among the patients with bile duct stone in the present study, moreover, since attainment to the papilla and subsequent treatment are more difficult in the patients with Billroth II-reconstructed stomach than usual patients, it may be better to perform MRCP at first and then to follow-up the patients without conducting the ERCP, as much as possible, if no stone is identified\[[@B28]-[@B30]\]. The treatment with endoscope on biliopancreatic disease in the patients with Billroth II-reconstructed stomach is less invasive, which is considered the treatment to be tried at first. Since there are some patients who present difficulty in treatment with endoscope, however, we should consider percutaneous approaches and surgical treatment if the percutaneous method is difficult, without sticking to the endoscopic treatment exclusively.

In conclusion, it was considered that ERCP for biliopancreatic diseases in patients with Billroth II-reconstructed stomach will become a less invasive, safe and useful examination and treatment approach.
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